11MO - Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) & pembrolizumab in 2nd line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors (ID 420)
Session NameSpeakers
- Margarita Majem (Barcelona, Spain)
DateFri, 31.03.2023Time08:15 - 09:15RoomAuditorium 1Duration5 Minutes
at the euro congress in 6 weeks
- Forums
- ASX - By Stock
- IMM
- Ann: TACTI-002 data presented at SITC for Efti in 1st line NSCLC
Ann: TACTI-002 data presented at SITC for Efti in 1st line NSCLC, page-7
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
41.0¢ |
Change
0.005(1.23%) |
Mkt cap ! $588.3M |
Open | High | Low | Value | Volume |
41.0¢ | 41.5¢ | 40.5¢ | $285.9K | 696.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 125726 | 40.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
41.0¢ | 30019 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
14 | 125726 | 0.405 |
16 | 120910 | 0.400 |
11 | 162337 | 0.395 |
9 | 448810 | 0.390 |
6 | 54364 | 0.385 |
Price($) | Vol. | No. |
---|---|---|
0.410 | 25019 | 8 |
0.415 | 172045 | 12 |
0.420 | 508600 | 12 |
0.425 | 77529 | 9 |
0.430 | 35281 | 8 |
Last trade - 10.54am 13/09/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |